AIM ImmunoTech Inc. has entered into agreements to convert a promissory note into shares of its common stock. According to a filing dated September 8, 2026, the company executed two exchange agreements with Streeterville Capital, LLC. These agreements relate to a Promissory Note dated November 18, 2025.
Under the terms of the agreements, approximately $400,000 of the outstanding promissory note was converted into 1,749,434 shares of the Company’s common stock. The conversion was executed at an average price of approximately $0.228 per share.
The issuance of these shares is exempt from registration requirements under Section 3(a)(9) of the Securities Act of 1933. This exemption applies because the securities are exchanged by the Company with an existing security holder, with no commission or remuneration paid for soliciting the exchange.
The conversion was previously approved by the Company’s stockholders. The approval was granted at a special meeting held on July 15, 2026, in accordance with NYSE American Company Guide Sections 713(a) and 713(b).
